USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Verrica Pharmaceuticals Q3 revenue beats estimates, but loss per share misses consensus

Earnings Whispers · ·by G4L

VRCA
VRCA Verrica Pharmaceuticals Inc
$3.56 -4.30%
View chart & analysis →
  1. 1Verrica Pharmaceuticals' Q3 revenue of $6.91 million exceeded expectations by 12.4%.
  2. 2Verrica Pharmaceuticals' Q3 GAAP loss per share of $0.58 missed consensus by 16.0%.
  3. 3Management stated that unit growth slowed due to the peak summer travel season.

So what's the key point?

What is the bottom line? Verrica Pharmaceuticals' Q3 revenue was 12.4% higher than expert expectations. However, the loss per share was larger than expected, which is a disappointing result for investors.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Verrica Pharmaceuticals Announces YCANTH Sales and VP-315 Development Plan The Motley Fool +1 · 8h agoAeluma reports fiscal Q1 revenue of $570,000, beating estimates Earnings Whispers · 11h agoVuzix Corp Q3 revenue down 38.5% and net loss widens Earnings Whispers · 11h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news